Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2016-04-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
独立董事苏志国2015年度述职报告
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of the company Beijing Shuanglu Pharmaceutical Co., Ltd. It covers the director's duties, attendance at board meetings, opinions on company decisions, compliance with regulations, and efforts to protect shareholder interests during the year 2015. The content is a formal report on the director's activities and responsibilities over the year, not a general annual report of the company or a financial statement. It is not a short announcement or certification but a substantive report on board/management information, specifically about the independent director's role and activities. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (3703 characters) is sufficient for a detailed report but not a full annual report or financial report. No financial statements or earnings data are included, so it is not an Annual Report (10-K) or Interim Report (IR).
2016-04-25 Chinese
2015年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2015 年度业绩快报' which translates to '2015 Annual Performance Express Report' or 'Earnings Quick Report'. It contains preliminary financial data for the full year 2015, including revenue, profit, net income, earnings per share, and asset information. The document explicitly states that the data is preliminary and unaudited, and it compares current year data with prior year data. It also discusses reasons for performance changes and differences from previous forecasts. The document length is 2222 characters, which is relatively short and suggests this is a brief earnings announcement rather than a full annual report. The content focuses on key financial highlights and performance metrics for the year, typical of an Earnings Release (ER). It is not a full Annual Report (10-K) or Interim Report (IR), nor is it an announcement of a report publication (RPA). Therefore, the best classification is Earnings Release (ER). FY 2015
2016-02-28 Chinese
2015年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2015 Third Quarter Report" of Beijing Shuanglu Pharmaceutical Co., Ltd. It contains detailed financial data for the quarter, including assets, net profit, earnings per share, and other financial indicators. It also includes shareholder information and notes on non-recurring gains and losses. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (third quarter) clearly indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q3 2015
2015-10-29 Chinese
2015年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled '2015 年第三季度报告' which translates to '2015 Third Quarter Report'. It contains detailed financial data including assets, net income, earnings per share, and shareholder information for the quarter. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters) and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2015
2015-10-29 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's external guarantees and related party fund occupation, referencing specific regulatory notices from the China Securities Regulatory Commission. It discusses compliance with laws and internal company regulations, and confirms no external guarantees or improper related party fund occupation during the reporting period ending June 30, 2015. The document is a standalone audit-related statement focusing on regulatory compliance and internal control matters, not a full annual or interim report, nor an announcement or presentation. It fits the category of Audit Report / Information (AR). The document length is short but contains substantive content, not merely an announcement or certification letter, so it is not RNS or RPA. H1 2015
2015-08-23 Chinese
2015年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2015 年半年度报告" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2015 Semi-Annual Report." It contains detailed financial data, accounting policies, business analysis, investment status, and management discussion for the first half of 2015 (reporting period: 2015-01-01 to 2015-06-30). The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content includes comprehensive financial statements and analysis, which fits the definition of an Interim / Quarterly Report (IR). It is not an announcement of a report publication, nor a certification or a short summary. Therefore, the document is classified as an Interim / Quarterly Report (IR). H1 2015
2015-08-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.